Kura Oncology (KURA) Total Current Liabilities (2010 - 2026)

Kura Oncology (KURA) has 17 years of Total Current Liabilities data on file, last reported at $101.5 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $101.5 million, up 13.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $101.5 million (up 13.07% YoY), and the FY2025 annual result was $117.0 million, up 48.61% from the prior year.
• Total Current Liabilities fell to $101.5 million in Q1 2026 per KURA's latest filing, from $117.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $121.3 million in Q3 2025 and troughed at $17.7 million in Q1 2022.
• A 5-year average of $53.6 million and a median of $33.5 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities dropped 29.49% in 2022, then jumped 220.39% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $24.1 million in 2022, then soared by 46.58% to $35.3 million in 2023, then jumped by 123.21% to $78.7 million in 2024, then jumped by 48.61% to $117.0 million in 2025, then retreated by 13.23% to $101.5 million in 2026.
• Business Quant data shows KURA's Total Current Liabilities at $101.5 million in Q1 2026, $117.0 million in Q4 2025, and $121.3 million in Q3 2025.